Medicines

Alprolix^{® *} (eftrenonacog alfa)

Alprolix^® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B (HB). Alprolix can be used for all age groups.

ALTUVOCT^®* (efanesoctocog alfa)

ALTUVOCT^® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity.

Aspaveli^®/Empaveli^® ** (pegcetacoplan)

Aspaveli^®/Empaveli^® (pegcetacoplan) is indicated for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.

Doptelet^® (avatrombopag)

Doptelet^® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.

Elocta^®/Eloctate^{® *} (efmoroctocog alfa)

Elocta^®/Eloctate^® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A (HA). Elocta/Eloctate can be used for all age groups.

Gamifant^® (emapalumab)

Gamifant^® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

Kineret^® (anakinra)

Kineret^® (anakinra) is indicated for the treatment of cryopyrin-associated periodic syndrome (CAPS), rheumatoid arthritis (RA), familial Mediterranean fever (FMF), deficiency of interleukin-1 receptor antagonist (DIRA) and Still's disease including systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease.

Orfadin^® (nitisinone)

Orfadin^® (nitisinone) is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Orfadin is also indicated for the treatment of adult patients with alkaptonuria (AKU).

Synagis^® (palivizumab)

Synagis^® (palivizumab) is indicated for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease.

VONJO^® (pacritinib)

VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Zynlonta^® (loncastuximab tesirine)

Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.

Other medicines

• Akynzeo^® (netupitant/palonosetron)
• Aloxi^® (palonosetron)
• Jyseleca^® (filgotinib maleate)
• Kepivance^® (palifermin)
• Tegsedi^® (inotersen)
• Waylivra^® (volanesorsen)sen)

^*Sobi and Sanofi collaborate on the development and commercialisation of Alprolix, Elocta/Eloctate and ALTUVOCT.

^**Sobi and Apellis have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-US commercialization rights for systemic pegcetacoplan, and Apellis has exclusive US commercialisation rights for systemic pegcetacoplan.